XmAb14045 - Emerging Insight and Market Forecast - 2030

XmAb14045 - Emerging Insight and Market Forecast - 2030

  • February 2021 •
  • 30 pages •
  • Report ID: 6025030 •
  • Format: PDF
“XmAb14045 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Blastic Plasmacytoid Dendritic Cell Neoplasm in 7 Major Markets. A detailed picture of the XmAb14045 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

XmAb14045, also known as Vibecotamab, SQZ622 is a tumor-targeted bispecific antibody that contains both a CD123 binding domain and a cytotoxic T-cell binding domain (CD3). CD123 is a hallmark for hematological and lymphatic malignancies . XmAb14045 functions to “bring together” tumor cells expressing CD123 and cytotoxic T cells, which bind CD3. The T cells are then activated to kill the CD123- expressing target cells. It is a full-length immunoglobulin molecule designed to be dosed intermittently. The structural stability and modularity of XmAb Bispecific Fc domain has enabled the vibecotamab’s potency to balance anti-tumor activity with the reduction of immune toxicity that can result from T-cell activation.

Scope of the report
The report provides insights into:
? A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
? Elaborated details on regulatory milestones and other development activities have been provided in this report.
? The report also highlights the drug research and development activity details across the United States, Europe and Japan.
? The report also covers the patents information with an expiry timeline around XmAb14045.
? The report contains forecasted sales for XmAb14045 till 2030.
? Comprehensive coverage of the Eraly-stage emerging therapies (Phase I) for Blastic Plasmacytoid Dendritic Cell Neoplasm.
? The report also features the SWOT analysis with analyst insights and key findings of XmAb14045.

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

XmAb14045 Analytical Perspective
? In-depth XmAb14045 Market Assessment
This report provides a detailed market assessment of XmAb14045 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

? XmAb14045 Clinical Assessment
The report provides the clinical trials information of XmAb14045 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights
? In the coming years, the market scenario for Blastic Plasmacytoid Dendritic Cell Neoplasm is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
? The companies and academics are working to assess challenges and seek opportunities that could influence XmAb14045 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
? Other emerging products for Blastic Plasmacytoid Dendritic Cell Neoplasm are giving market competition to XmAb14045 and launch of late-stage emerging therapies in the near future will significantly impact the market.
? A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of XmAb14045.
? Our in-depth analysis of the forecasted sales data of XmAb14045 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the XmAb14045.

Key Questions
• Which company is developing XmAb14045 along with the phase of the clinical study?
• What is the technology utilized in the development of XmAb14045?
• What is the product type, route of administration and mechanism of action of XmAb14045?
• What is the clinical trial status of the study and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the XmAb14045 development?
• What are the key designations that have been granted to XmAb14045?
• What is the forecasted market scenario of XmAb14045?
• What is the history of XmAb14045 and what is its future?
• What is the forecasted sales of XmAb14045 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how these are giving competition to XmAb14045?
• Which are the late-stage emerging therapies under development for the treatment of the Blastic Plasmacytoid Dendritic Cells Neoplasm?